This handout is for aneurysmal sah — good grade (hunt-hess i–iii). Your care team identified this based on: thunderclap headache, gcs 15, no/minimal focal deficit (hh i–ii) [aha/asa 2023 hoh pmid 37212182].
Other reasons your team may use this plan: drowsiness or mild focal deficit (hh iii) with thunderclap [hunt-hess 1968; aha/asa 2023]; ct showing subarachnoid blood in alert patient (fisher i–iv) [aha/asa 2023]; cta demonstrates saccular aneurysm — entry to coiling/clipping pathway [aha/asa 2023; isat 2005].
Take these medications exactly as prescribed. Do not stop or change a dose without talking to your provider.
| Medication | Starting dose | How | When | What it does |
|---|---|---|---|---|
| nimodipine | 60 mg PO/NG q4h × 21 days | PO | q4h | BRANT (Pickard BMJ 1989 PMID 2496789) — Class I per 2023 AHA/ASA; reduces poor outcome from DCI. NEVER IV (FDA boxed warning — fatal hypotension). |
Plan: Good-grade aSAH (HH I–III) — early securing ≤24 h + nimodipine + BP <160 pre-secure + DCI rescue (AHA/ASA 2023 + NCS 2023)
Contact your care team if any of the following happen:
Call 911 or go to the nearest emergency room right away if you have:
Cerebrovascular clinic 6 wk / 3 / 6 / 12 mo; BP <130/80 (2025 AHA/ACC HTN); smoking cessation; family aneurysm screening if ≥2 first-degree relatives or ADPKD; rehab; cognitive eval (MoCA + PHQ-9); repeat MRA at 6 mo [AHA/ASA 2023]
Guideline: 2023 AHA/ASA aSAH Guideline (Hoh et al, Stroke 2023 PMID 37212182) + 2023 NCS aSAH Management (Treggiari et al, Neurocrit Care 2023 PMID 37202712)